Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Early initiation Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants

NCT01892085
View directory record Official record
Conditions
Breast Milk Expression
Interventions
Early initiation, Intermediate expression, Late initiation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 4, 2026, 11:35 PM EDT
Active, not recruiting Early Phase 1 Interventional

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874
View directory record Official record
Conditions
Breast Cancer, Early-Onset
Interventions
Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed No phase listed Observational

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

NCT02137200
View directory record Official record
Conditions
Pregnancy
Interventions
Immediate pushing, Delayed pushing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Phase 2 Interventional

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

NCT07315165
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Interventions
Enteral Nutrition
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Early Phase 1 Interventional

Regional Monitoring of CF Lung Disease

NCT06339593
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Airway-clearance vest, Hyperpolarized Xe129
Procedure · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

The "Reach For Health" Program: Delaying Sexual Activity in Children

NCT00059241
View directory record Official record
Conditions
Sex Behavior, Child Behavior
Interventions
Parent-child communication education, Service learning, Classroom health curriculum
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 14 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 11:35 PM EDT
Completed No phase listed Observational

A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

NCT04721366
View directory record Official record
Conditions
Gaucher Disease
Interventions
Standard of Care
Other
Lead sponsor
Takeda
Industry
Eligibility
Up to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 4, 2026, 11:35 PM EDT
Not yet recruiting Phase 2 Interventional

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

NCT07560826
View directory record Official record
Conditions
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Interventions
High-dose Methotrexate
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 22 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study

NCT04608019
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Antibiotics, Tailored Treatment
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
6 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

NCT03318497
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 4, 2026, 11:35 PM EDT
Terminated Phase 3 Interventional

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

NCT00005774
View directory record Official record
Conditions
Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions
Early surfactant, Standard practice
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, atenolol, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting No phase listed Observational

Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF

NCT06849752
View directory record Official record
Conditions
Heart Failure, Socioeconomic Adversity
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional Results available

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

NCT00660543
View directory record Official record
Conditions
Adult Brain Glioblastoma
Interventions
Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 4, 2026, 11:35 PM EDT
Not yet recruiting Phase 4 Interventional

Ketamine for the Treatment of Refractory Status Epilepticus

NCT07177235
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 4, 2026, 11:35 PM EDT
Recruiting Phase 1 Interventional

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776
View directory record Official record
Conditions
GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Tacrolimus, Early Tacrolimus Taper Strategy
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Not applicable Interventional

Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)

NCT03636568
View directory record Official record
Conditions
Hyponatremia, Hyponatremic, Pituitary Tumor, Pituitary, Surgery
Interventions
Fluid Restricted Group
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 4, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 11:35 PM EDT
Active, not recruiting Early Phase 1 Interventional

Zr89 + PET Companion Trial

NCT05279027
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Zirconium Zr 89 Crefmirlimab Berdoxa
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 11:35 PM EDT